409 Illinois Street
About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review in China by the State Drug Administration (SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
174 articles with FibroGen, Inc.
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
FibroGen, Inc. announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 infection.
FibroGen, Inc. announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience.
FibroGen, Inc. (NASDAQ:FGEN) announced data from three roxadustat clinical trials, including the Phase 3 DOLOMITES study evaluating roxadustat for treatment of anemia in non-dialysis-dependent CKD patients compared to darbepoetin alfa, and ophthalmology findings from a Japan Phase 3 study evaluating roxadustat compared to darbepoetin alfa in patients on hemodialysis
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United States with Severe COVID-19
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences
FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May 12-14, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 11:00 AM Eastern Time on Thursday, May 14. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen website at www.fibrogen.com. A replay of the fireside chat will be a
FibroGen, Inc. reported financial results for the first quarter of 2020 and provided an update on the company’s recent developments.
FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at https:/
FibroGen, Inc. announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors to be invalid.
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year of 2019 and provided an update on the company’s recent development
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020. FibroGen will also conduct a conference call on that day at 5:00 p.m. (2:00 p.m. PT)
FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 3:30 PM Eastern Time
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
FibroGen, Inc. announced that the U.S. Food and Drug Administration has completed its filing review of its New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease, in both non-dialysis-dependent and dialysis-dependent patients.
Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan
Astellas Pharma Inc. and FibroGen, Inc. announced the submission of a supplemental New Drug Application to Japan's Ministry of Health, Labour and Welfare to gain marketing approval for Evrenzo® for the treatment of anemia associated with chronic kidney disease in non-dialysis dependent patients.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
1/10/2020Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments.
FibroGen Names Enrique Conterno as Chief Executive OfficerConterno brings global pharmaceutical leadership from his three decades of industry experience
FibroGen, Inc. announced that its Board of Directors unanimously appointed Enrique Conterno as the company’s Chief Executive Officer and a member of the Board of Directors.
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney DiseaseNew Drug Application supported by positive global Phase 3 efficacy and safety results
FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD patients.
FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA).